CNS Pharmaceuticals Statistics Share Statistics CNS Pharmaceuticals has 574.58K
shares outstanding. The number of shares has increased by -11.5%
in one year.
Shares Outstanding 574.58K Shares Change (YoY) -11.5% Shares Change (QoQ) 0% Owned by Institutions (%) 3.2% Shares Floating 573.5K Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 38.51K, so 6.7% of the outstanding
shares have been sold short.
Short Interest 38.51K Short % of Shares Out 6.7% Short % of Float 6.7% Short Ratio (days to cover) 1.21
Valuation Ratios The PE ratio is -1.54 and the forward
PE ratio is -0.44.
CNS Pharmaceuticals's PEG ratio is
0.04.
PE Ratio -1.54 Forward PE -0.44 PS Ratio 0 Forward PS n/a PB Ratio 3.71 P/FCF Ratio -1.34 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for CNS Pharmaceuticals.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.43,
with a Debt / Equity ratio of 0.05.
Current Ratio 3.43 Quick Ratio 3.43 Debt / Equity 0.05 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage -924.5
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.71M Employee Count 4 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0.64, so CNS Pharmaceuticals's
price volatility has been higher than the market average.
Beta 0.64 52-Week Price Change n/a 50-Day Moving Average 8.2 200-Day Moving Average 31.19 Relative Strength Index (RSI) 41.95 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit -3.31K Operating Income -14.9M Net Income -14.86M EBITDA -14.9M EBIT -14.87M Earnings Per Share (EPS) -38.87
Full Income Statement Balance Sheet The company has 6.46M in cash and 326.07K in
debt, giving a net cash position of 6.14M.
Cash & Cash Equivalents 6.46M Total Debt 326.07K Net Cash 6.14M Retained Earnings -84.42M Total Assets 14.51M Working Capital 12.75M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -17.11M
and capital expenditures -4.19K, giving a free cash flow of -17.12M.
Operating Cash Flow -17.11M Capital Expenditures -4.19K Free Cash Flow -17.12M FCF Per Share -53.95
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields CNSP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for CNSP.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 22, 2025. It was a
backward
split with a ratio of 1:12.
Last Split Date Jul 22, 2025 Split Type backward Split Ratio 1:12
Scores Altman Z-Score -9.69 Piotroski F-Score 2
